|
1
|
Lambea J, Anido U, Etxániz O, Flores L,
Montesa Á, Sepúlveda JM and Esteban E: The wide experience of the
sequential therapy for patients with metastatic renal cell
carcinoma. Curr Oncol Rep. 18:662016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rathmell WK and Chen S: VHL inactivation
in renal cell carcinoma: Implications for diagnosis, prognosis and
treatment. Expert Rev Anticancer Ther. 8:63–73. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gnarra JR, Tory K, Weng Y, Schmidt L, Wei
MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al: Mutations of the
VHL tumour suppressor gene in renal carcinoma. Nat Genet. 7:85–90.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cancer Genome Atlas Research Network:
Comprehensive molecular characterization of clear cell renal cell
carcinoma. Nature. 499:43–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Folkman J: The role of angiogenesis in
tumor growth. Semin Cancer Biol. 3:65–71. 1992.PubMed/NCBI
|
|
6
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomisawa M, Tokunaga T, Oshika Y, Tsuchida
T, Fukushima Y, Sato H, Kijima H, Yamazaki H, Ueyama Y, Tamaoki N
and Nakamura M: Expression pattern of vascular endothelial growth
factor isoform is closely correlated with tumour stage and
vascularisation in renal cell carcinoma. Eur J Cancer. 35:133–137.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bhargava P and Robinson MO: Development of
second-generation VEGFR tyrosine kinase inhibitors: Current status.
Curr Oncol Rep. 13:103–111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin
ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu
EY, et al: Nonclinical antiangiogenesis and antitumor activities of
axitinib (AG-013736), an oral, potent, and selective inhibitor of
vascular endothelial growth factor receptor tyrosine kinases 1, 2,
3. Clin Cancer Res. 14:7272–7283. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motzer RJ, Hutson TE, Cella D, Reeves J,
Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et
al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan H, Cai P, Li Q, Wang W, Sun Y, Xu Q
and Gu Y: Axitinib augments antitumor activity in renal cell
carcinoma via STAT3-dependent reversal of myeloid-derived
suppressor cell accumulation. Biomed Pharmacother. 68:751–756.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pal SK, Hossain DM, Zhang Q, Frankel PH,
Jones JO, Carmichael C, Ruel C, Lau C and Kortylewski M: Pazopanib
as third line therapy for metastatic renal cell carcinoma: Clinical
efficacy and temporal analysis of cytokine profile. J Urol.
193:1114–1121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Azuma T, Yao S, Zhu G, Flies AS, Flies SJ
and Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer
cells. Blood. 111:3635–3643. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schvartsman G, Peng SA, Bis G, Lee JJ,
Benveniste MFK, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach
JV, et al: Response rates to single-agent chemotherapy after
exposure to immune checkpoint inhibitors in advanced non-small cell
lung cancer. Lung Cancer. 112:90–95. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ogawara D, Soda H, Iwasaki K, Suyama T,
Taniguchi H, Fukuda Y and Mukae H: Remarkable response of
nivolumab-refractory lung cancer to salvage chemotherapy. Thorac
Cancer. 9:175–180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Atkins MB, Plimack ER, Puzanov I, Fishman
MN, McDermott DF, Cho DC, Vaishampayan U, George S, Olencki TE,
Tarazi JC, et al: Axitinib in combination with pembrolizumab in
patients with advanced renal cell cancer: A non-randomised,
open-label, dose-finding, and dose-expansion phase 1b trial. Lancet
Oncol. 19:405–415. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Albiges L, Fay AP, Xie W, Krajewski K,
McDermott DF, Heng DY, Dariane C, DeVelasco G, Lester R, Escudier B
and Choueiri TK: Efficacy of targeted therapies after PD-1/PD-L1
blockade in metastatic renal cell carcinoma. Eur J Cancer.
51:2580–2586. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fidler IJ: The pathogenesis of cancer
metastasis: The ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen L, Azuma T, Yu W, Zheng X, Luo L and
Chen L: B7-H1 maintains the polyclonal T cell response by
protecting dendritic cells from cytotoxic T lymphocyte destruction.
Proc Natl Acad Sci USA. 115:3126–3131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiou VL and Burotto M: Pseudoprogression
and immune-related response in solid tumors. J Clin Oncol.
33:3541–3543. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fujimoto D, Yoshioka H, Kataoka Y,
Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara
S, et al: Pseudoprogression in previously treated patients with
non-small cell lung cancer who received nivolumab monotherapy. J
Thorac Oncol. Nov 20–2018.(Epub ahead of print). View Article : Google Scholar
|
|
30
|
Tsushima F, Yao S, Shin T, Flies A, Flies
S, Xu H, Tamada K, Pardoll DM and Chen L: Interaction between B7-H1
and PD-1 determines initiation and reversal of T-cell anergy.
Blood. 110:180–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ko JS, Zea AH, Rini BI, Ireland JL, Elson
P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al:
Sunitinib mediates reversal of myeloid-derived suppressor cell
accumulation in renal cell carcinoma patients. Clin Cancer Res.
15:2148–2157. 2009. View Article : Google Scholar : PubMed/NCBI
|
